Czech confusion over pseudoephedrine status

16 March 2009

A conflict has developed between the Czech Republic's Health Minister, Daniela Filipiova, and the Parliament over the control of cold and  influenza products containing pseudoephedrine. A recent draft law  presented to the legislature now includes an amendment to classify the  active ingredient as an addictive substance for prescription only. Ms  Filipiova opposes this move, partly on the grounds that forcing more  people with colds to visit physician surgeries is a waste of time and  will increase the risk of other patients being infected.

The ingredient is used in the manufacture of the illegal narcotic  methylamphetamine. The Health Minister argues that the new requirement  for pharmacists to be shown an insurance card before selling cold or  flu remedies will enable suspiciously large numbers of transactions to  be monitored.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight